{'fraction_non_alphanumeric': 0.022569444444444444, 'fraction_numerical': 0.006944444444444444, 'mean_word_length': 5.709302325581396, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[New therapeutic approach to pancreatic cancer by monoclonal antibodies].

The prognosis of pancreatic cancer is extremely poor in digestive cancers even with systemic therapy including surgery. Thus development of a new therapeutic approach is awaited. Recently, new trials of cancer treatments using monoclonal antibodies conjugated with anti-cancer drugs or labeled with isotopes have been reported. Here, we discuss the possible therapeutic application for pancreatic cancer of adriamycin-conjugated and 131I-labeled Nd2, which is produced against pancreatic cancer mucin.